Clinical trial
Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron…
NCT00067080 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00067080 |
|---|---|
| Title | Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions |
| Official title | A Randomized, Open Label, Phase II Study on Safety and Efficacy of Long Term Treatment of ICL670 Relative to Deferoxamine in Sickle Cell Disease Patients With Transfusional Hemosiderosis |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anemia, Sickle Cell |
| Intervention type | Drug |
| Interventions | ICL670, deferoxamine |
| Enrollment | 195 |
| Start date | May 1, 2003 |
| Primary completion | Jul 1, 2007 |
| First posted | Aug 13, 2003 |
| Last update posted | Aug 22, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: